DÉCLARATION DE NOTIFICATION
Incident de cybersécurité chez le fabricant et fournisseur d’immunothérapie allergénique HAL Allergy B.V. Dans la soirée du samedi 28 octobre, HAL Allergy a été victime d’une attaque par ransomware. Grâce…
Lees verder KENNISGEVING
Cyberbeveiligingsincident bij allergeenimmunotherapiefabrikant en -leverancier HAL Allergy B.V. In de avond van zaterdag 28 oktober werd HAL Allergy getroffen door een ransomware aanval. Dankzij de tijdige interventie van het IT…
Lees verder Alex Huybens appointed as Chief Executive Officer (CEO) of HAL Allergy Holding B.V. and HALIX B.V.
Leiden (The Netherlands, 01.07.2021) – As of 1 July 2021, the Supervisory Board of the HAL Allergy Group has appointed Alex Huybens as Chief Executive Officer (CEO) and Member of…
Lees verder HAL Allergy S.r.l. and Avalon Counseling start telephone counseling to support doctors and medical personnel in the regions most affected by coronavirus
Telephone counseling for all hospital staff members in the regions of Lombardy, Emilia Romagna, Veneto, Piedmont Rome, Italy, (March 26, 2020) – Today, HAL Allergy S.r.l. announced the start of…
Lees verder Dr. Hans van Schijndel appointed as Chief Research & Development Officer of HAL Allergy Holding B.V.
Dear all, We are very pleased to announce that the Supervisory Board has appointed Dr. Hans van Schijndel as Member of the Board of HAL Allergy Holding B.V. in the…
Lees verder HAL Allergy first company to achieve marketing authorisations in line with Therapieallergene-Verordnung (TAV) in Germany
Registration of SUBLIVAC® Birch and SUBLIVAC® Trees 40.000 AUN/ml in Germany accomplished Leiden, the Netherlands (14 August 2018) – HAL Allergy B.V. today announced the registration of SUBLIVAC® Birch 40.000 AUN/ml and SUBLIVAC® Trees 40.000 AUN/ml…
Lees verder